A gainst all odds, the box of pills is cute. On one side of its winsome cardboard shell, a custom typeface spells out the brand name, Hims, in all lowercase, giving off a vibe somewhere between an e.e. cummings poem and a retro zine. A pamphlet that comes with the drug—Addyi, a controversial pill that aims to increase female libido—trades in millennial-empowerment language worthy of Goop. “Future you thank you,” it begins, followed by a string of rah-rah slogans like “balance is everything” and “you’re not alone.” Also included: a stylized postcard of a woman joyfully watering plants in a pair of clogs. The minimalist white pill bottle would blend in on a shelf at an Apple Store.
Hims Inc. is a 3-year-old telehealth company in San Francisco. This year, as the pandemic created a surge of demand for online medical care, the startup began providing Covid-19 tests as well as primary care and mental health services. Mostly, though, it’s known for offering generic prescription drugs to treat erectile dysfunction and hair loss. Customers fill out an online questionnaire, perhaps exchange a few messages with a prescribing physician, then get the medication shipped to their homes without having to take a separate trip to the doctor. For this service, Hims charges a premium. It sells a month’s worth of a generic version of Viagra for $4 per 40- milligram pill; at local pharmacies, a larger 50mg dose costs as little as $1.70 each with a coupon.
In Hims ads and on the company’s website, the products’ relevant medical information is scattered among hyperphallic cacti, eggplant emojis, and a cartoon Snoop Dogg. As with other mail-order brands of the past decade, such as Casper and Warby Parker—which sell mattresses and eyeglasses, respectively—the packaging is central to the sales pitch. In an interview conducted pre-Covid, Chief Executive Officer Andrew Dudum says his goal was to build a health-care delivery system with the inviting gloss of Instagram. “When you use it, endorphins are rushing through your body,” Dudum says of the photo-sharing site. “That currently doesn’t happen in the health system, which is a big problem. It’s an ugly experience.”
Insufficiently grabby marketing of white-label libido pills wouldn’t top many lists of problems with U.S. health care. The country’s 330 million citizens pay at least twice the going global rates for most pharmaceuticals. And for the roughly 30 million who lack health insurance, costs are usually far higher.
Still, as the pandemic has widened the gaping holes in America’s fragile health-care system, Hims has capitalized on priorities further up Maslow’s hierarchy of needs. Its shiny veneer, wellness lingo, and ability to prescribe over the internet have helped attract more than a quarter- million subscribers to its upmarket commodities over the past three years. It says it’s profitable and on track to bring in $138 million in revenue this year, up 66% from 2019. In October, Hims announced plans to go public by the end of the year through a merger with a special-purpose acquisition company spun out of Oaktree Capital Management, a deal that values Hims at about $1.6 billion. To date, investors have supplied Hims with more than $200 million in venture funding.
The Oaktree timetable means that Hims will likely be the first of a slew of similar telemedicine companies to join the public markets as the need for remote doctoring grows. These businesses market treatments for everything from ADHD to aging. Dudum says he’s interested in expanding into such conditions as diabetes, hypertension, high cholesterol, insomnia, and infertility in the coming years, bringing the company’s marketing expertise to a much wider range of chronic conditions. “We’re at the beginning of what I believe is 10, 20 years of growth for this company,” he says, adding that Hims is “at the forefront of innovation and health care.”
And yet Hims’s real innovation isn’t in destigmatizing embarrassing medical conditions. It’s in making prescriptions extremely easy to get—maybe too easy, critics say. Interviews with six current and former Hims doctors, as well as interviews with other employees and recordings of company phone calls shared with Bloomberg Businessweek, suggest that Hims has pushed the bounds of medical ethics. Each of its 200-odd doctors sees hundreds of patients a week. Often, doctors prescribe Hims drugs for uses the U.S. Food and Drug Administration hasn’t approved. (In one ad, which Hims says it’s removed from its social media campaigns, it pitched a blood-pressure drug, sometimes prescribed for anxiety, as a way to calm down before a big date.) U.S. doctors are allowed to prescribe drugs at their discretion, but pharmaceutical companies aren’t allowed to market medications for off-label uses, and it’s unclear whether such rules might apply to Hims. Many states also forbid companies from instructing doctors on how to do their jobs.
Continue reading your story on the app
Continue reading your story in the magazine
The Most Broken Business in America
Biden’s Build Back Better plan may make day care more affordable for parents—if the providers don’t go belly up first
Don’t let their confidence fool you: Xi, Putin, and other authoritarians are increasingly vulnerable at home
The Gucci Girlfriend
A love affair with Sheree McLaughlin led fashion scion Maurizio Gucci to leave his wife—a decision that would get him killed. As audiences ready for Ridley Scott’s retelling in House of Gucci, McLaughlin shares her story for the first time.
Crypto's Regulation Fix: We'll Handle It
Execs say traditional agencies don’t have the tools or expertise to oversee the sector alone
Ghost at the Controls
Boeing insisted pilots didn’t need expensive training for the new 737 Max and wouldn’t have trouble diagnosing software errors midflight. Then Maxes started pointing themselves toward the Earth. Adapted from the new book Flying Blind: The 737 Max Tragedy and the Fall of Boeing, by Peter Robison
Xi's Great Moderation
The Chinese leader wants to downsize the real estate sector, even if it means sacrificing economic growth
There's a Blockchain App for That
○ The technology is being used for digital health passports, banking, and gaming
Teaching Digital Currencies Not to Guzzle
Alternatives to “mining” augur power-sipping coins
Rivian's Success Is a Tribute to Tesla
Why is a company with no sales worth $130 billion? Belief in EVs
Retailers Gain The Upper Hand
○ Supply chain disruptions will mean fewer deep discounts for shoppers this Christmas
The Soft Sell
The healthcare brand Hims wants to leverage young men’s anxiety over erections and hair loss into a multibillion-dollar empire. It’s been harder than expected.
Just What The Patient Ordered
A slew of well-funded startups are making it easier than ever to get prescription medications online, turning patients into customers—and doctors into something akin to assembly-line safety inspectors. As with everything, there are side effects.
दिल्ली में रहने वालों को अब मिलेगा हेल्थ कार्ड
एक छत के नीचे मिलेंगी मेडिकल फैसिलिटी
‘It used to be SEVEN BEDSITS!'
Emma and Matt’s blend of Victorian detail, antique finds and colour hits has created a unique and eclectic family home
The EV Disruptor
A cashed-up start-up deigns to take on taycan and tesla with ‘the world’s most efficient ev’. Meet the lucid air – and the tech giving it an 800km range and 783kw of electric grunt
Men are now flashing their junk on video calls
During a Zoom conference call simulating the US election among journalists at The New Yorker last week, staff writer Jeffrey Toobin was allegedly caught playing with himself.
Plugging into the future
One of the biggest revelations for the luxury auto industry this year is that going electric is no longer an option – and it must be done now.
The Spirit Is A Person And Wants A Relationship With Us!
One of the guest speakers at next year’s Elim Summit is Soul Survivor legend Mike Pilavachi. Mike, who surprisingly ended the popular youth festival this summer, is a long-term friend of Elim. Here he answers some questions about the Holy Spirit.